Humoral and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients
In this study we evaluated myeloproliferative neoplasm patients' serologic and T-cell responses 1 month after SARS-CoV-2 vaccination. While response rates were overall high, subtle deficiencies in T-cell responses likely indicate some impaired cellular immunity that requires further investigation.
